Actavis CEO: Teva-Mylan deal could be "value-destroying" - Globes
Teva Pharmaceuticals found to be responsible for its role in the opioid epidemic in New York State | CNN
Teva stock drops after conspiracy allegations on hiking drug prices
Teva CEO Rejects Netanyahu Plea to Salvage Jerusalem Plant - Bloomberg
Teva Is 'on the Way' to Leaving Opioid Litigation Behind, CEO Says | Barron's
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Adderall Shortages Spread to 4 Pharmaceutical Companies Including Teva, Novartis - Bloomberg
Teva shares jump in Tel Aviv after report of up to 10,000 job cuts | The Times of Israel
Activist Investor Jana Partners Takes Stake in Teva, Report Says | Ctech
The Difficulties of Cloning a CEO - Bloomberg
Teva to Pay $85 Million Settlement in Oklahoma Opioid Case - Bloomberg
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
Teva Is at Center of Drug Price-Fixing Case Filed by States - Bloomberg
Teva CEO Calls 'Trough' Revenues Consequence of Patent Expirations - YouTube
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
Teva makes $40.1 billion takeover bid for Mylan | Mint
Teva to Sell Record $5 Billion of Sustainability-Linked Bonds - BNN Bloomberg
Teva Is Facing Adderall Supply Disruptions as Demand for ADHD Drug Soars - BNN Bloomberg
Teva shares plummet amid CEO departure and bribery reports
Teva Generic Price-Fixing Securities Suit Gets Class Status (1)
Teva Shows Progress on Restructuring But Investors Want More - TheStreet
Future Teva CEO Seeks to 'Formulate Clear Strategy' - YouTube
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
